What Is PCOS? Epidemiology and Diagnostic Criteria
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders, affecting approximately 8–13% of women of reproductive age. According to World Health Organization data, it affects more than 116 million women worldwide. Diagnosis according to the Rotterdam Criteria requires at least two of the following: oligo/anovulation, polycystic ovarian morphology (≥12 antral follicles on ultrasound or ovarian volume >10 mL), and clinical/biochemical hyperandrogenism. Other causes of androgen excess must first be excluded.
The clinical presentation varies depending on the PCOS phenotype. The classic phenotype (types A and B) is associated with the most pronounced hormonal picture, while ovulatory PCOS (type C) and the normoandrogenic phenotype (type D) may follow a milder course. Skin and hair findings are most frequently observed in the classic phenotype.
The Androgen Mechanism: Biological Effects on Skin and Hair Follicles
In PCOS, elevated androgen levels — particularly free testosterone, dihydrotestosterone (DHT), and dehydroepiandrosterone sulfate (DHEAS) — directly stimulate androgen receptors in the skin and hair follicles. This process operates through three key axes and leads to both visible and functional changes:
- Increased sebum production: Androgens activate the 5-alpha reductase type 1 enzyme in sebaceous glands, increasing sebum secretion by 20–30%. Excess sebum creates a substrate for C. acnes proliferation, triggering the inflammatory acne cascade.
- Hair follicle stimulation: DHT binds to receptors in androgen-sensitive body and facial hair follicles, stimulating terminal hair growth and causing hirsutism. Paradoxically, the same hormone shortens the follicular cycle in scalp follicles, leading to androgenetic alopecia.
- Insulin resistance synergy: Insulin resistance accompanies PCOS in 50–70% of patients. Hyperinsulinaemia reduces hepatic sex hormone-binding globulin (SHBG) synthesis, increasing free androgen levels. Androgen synthesis is further amplified via IGF-1, intensifying inflammatory signals in the skin.
A clinically critical point: normalising androgen levels without first bringing insulin resistance under control is difficult. PCOS skin treatment must therefore also encompass measures to improve insulin sensitivity.
Hormonal Acne in PCOS: Clinical Features and Differential Diagnosis
PCOS-related acne differs markedly from classic adolescent acne. Accurate diagnosis directly determines treatment success.
| Feature | PCOS Acne | Classic Acne Vulgaris |
|---|---|---|
| Distribution | Chin, mandible, neck, lower cheeks | Forehead, nose, upper cheeks (T-zone) |
| Timing of flares | Luteal phase of the menstrual cycle | Hormonal correlation less pronounced |
| Lesion type | Deep, cystic, painful nodules | Mixed type (comedones + papules) |
| Response to topical therapy | Insufficient; hormonal intervention required | Responds to retinoids/antibiotics |
| Associated findings | Hirsutism, irregular periods, oily skin | Typically isolated |
A meta-analysis published in the Journal of the American Academy of Dermatology (2024) found a significant positive correlation between free testosterone levels and acne severity (IGA score) in patients with PCOS-related acne (r=0.68, p<0.001). At Virtuana Clinic, hormonal acne consultations begin with a biochemical panel assessment, after which the medical aesthetic protocol is planned.
Acne Treatment in PCOS: A Stepwise Protocol
A single-modality approach is insufficient for PCOS acne. An effective strategy includes the following steps:
- Hormonal suppression: Control of androgen excess with combined oral contraceptives (particularly anti-androgenic progestins: drospirenone, cyproterone acetate) or spironolactone (25–200 mg/day). Without this step, all other treatments provide only temporary benefit.
- Retinoid therapy: Topical adapalene or tretinoin prevents comedone formation and reduces inflammatory papules. Isotretinoin may be considered in resistant cases.
- Medical aesthetic adjuncts: Chemical peeling (salicylic acid 20–30%, mandelic acid), LED phototherapy (415 nm blue light), carbon peeling combination. These procedures address active lesions while also targeting post-acne scarring.
- PIH (post-inflammatory hyperpigmentation) treatment: Tranexamic acid mesotherapy, laser toning (Q-switched Nd:YAG), topical azelaic acid.
Hirsutism: Assessment Scale and Treatment Options
Hirsutism is defined as excessive terminal hair growth in androgen-sensitive areas in women (face, neck, chest, midline abdomen, inner thighs). It is assessed using the Modified Ferriman-Gallwey Score; a score of 8 or above is defined as clinical hirsutism. Prevalence in PCOS can reach 65–70%.
| Method | Mechanism of Action | Efficacy | Clinical Note |
|---|---|---|---|
| Combined hormonal contraceptive (CHC) | Androgen suppression, SHBG increase | 60–70% reduction (at 6 months) | Systemic first-line treatment |
| Spironolactone (25–200 mg/day) | Androgen receptor antagonist, 5α-reductase inhibition | 70–80% reduction | Synergistic in combination with CHC |
| Nd:YAG / Diode Laser Epilation | Follicular photothermolysis; melanin-targeted | 80–90% permanent reduction (8 sessions) | Should begin after hormonal stabilisation |
| IPL (Intense Pulsed Light) | Broad-spectrum light follicular damage | 60–75% reduction | For Fitzpatrick I–III; caution with darker skin tones |
| Electrolysis | Permanent follicle destruction via galvanic current | 95%+ permanent | Gold standard for small areas; slow |
| Eflornithine cream (11.5%) | Ornithine decarboxylase inhibitor; slows hair growth | 35–40% slowing | Additional benefit when combined with laser |
In the Virtuana Clinic PCOS hirsutism protocol, 3–6 months of hormonal suppression is achieved before laser epilation begins. This strategy both improves efficacy and reduces the total number of sessions required by 30–40%.
Androgenetic Alopecia: Pathogenesis of Hair Loss in PCOS
Hair loss in PCOS most commonly follows a pattern consistent with Ludwig Classification Type I–II: diffuse thinning and widening at the crown with largely preserved frontal hairline. Some patients may also experience bitemporal recession.
DHT is central to the pathophysiology. The 5-alpha reductase type 2 enzyme in scalp follicles converts testosterone to DHT. DHT dramatically shortens the growth phase (anagen: 3–6 years), prolongs the resting phase (telogen), and progressively miniaturises follicles — converting thick terminal hairs into fine, colourless vellus hairs. This process is reversible in its early stages, making early diagnosis critically important.
An important point to note: in PCOS, the severity of hair loss is determined not only by androgen levels but also by the density of androgen receptors in the follicle and local 5-alpha reductase activity. As a result, some patients may experience significant alopecia even with normal testosterone levels.
Hair Loss in PCOS: Diagnostic Algorithm and Laboratory Investigations
Accurate diagnosis is essential to avoid unnecessary treatments and to plan an effective protocol. The evaluation process includes:
- Trichoscopy: Follicular calibre variation (>20% miniaturised follicles is significant for androgenetic alopecia), perifollicular pigmentation, yellow dots and inter-hair calibre differences are assessed.
- Hormone panel: Total and free testosterone, DHEAS, prolactin, FSH, LH, SHBG, insulin, HOMA-IR
- Thyroid panel: TSH, fT3, fT4 — thyroid disease must be excluded as a co-diagnosis
- Full blood count and biochemistry: Ferritin (target ≥70 ng/mL), serum iron, transferrin saturation, B12, folic acid, zinc, vitamin D
- Skin biopsy: Only in cases of diagnostic difficulty; helpful in distinguishing from telogen effluvium
| Treatment | Mechanism of Action | Evidence Level | Expected Outcome |
|---|---|---|---|
| Topical minoxidil (2–5%) | Potassium channel opener, follicular vasodilator, anagen prolongation | A (FDA approved) | 15–25% increase in hair shaft diameter by week 16 |
| Spironolactone (oral, 100–200 mg/day) | Anti-androgenic; reduces follicular DHT effect | B | Reduction in hair shedding from month 6 |
| PRP (Platelet-Rich Plasma) | Release of PDGF, VEGF, EGF; follicular proliferation | B (12+ RCTs) | 25–35% increase in hair count after 3 sessions |
| Stem cell mesotherapy cocktail | Growth factors, biotin, zinc — local nutritional support | C | Anagen stimulation, improvement in hair quality |
| LLLT (Low-Level Laser Therapy) | Photobiomodulation; mitochondrial ATP increase, reduced oxidative stress | B (FDA-cleared devices) | Significant increase in hair shaft diameter at 26 weeks |
| Polynucleotide (PDRN) scalp injection | A2 adenosine receptor activation; tissue repair, angiogenesis | C (emerging data promising) | Synergistic effect in combination with PRP |
Acanthosis Nigricans: A Visible Marker of Insulin Resistance
Acanthosis nigricans (AN) is a darkened (hyperpigmented), velvety skin thickening that develops in the nape, axillae, groin, and neck folds. It occurs in 30–50% of patients with PCOS and is a reliable dermatological marker of insulin resistance. In the pathogenesis, hyperinsulinaemia stimulates IGF-1 receptors on keratinocytes and fibroblasts, leading to excessive proliferation.
The presence of AN alone should raise suspicion of insulin resistance in PCOS and necessitate HOMA-IR calculation. The cornerstone of treatment is controlling the underlying insulin resistance:
- Metformin (500–2000 mg/day, under endocrinologist supervision): Improves insulin sensitivity; significant regression of AN findings within 6–12 months.
- GLP-1 receptor agonists (semaglutide, liraglutide): Promising newer options for insulin resistance and weight management.
- Topical adjuncts: Retinoid creams (0.05–0.1%), 10–12% ammonium lactate lotion, salicylic acid-based exfoliants — reduce superficial thickening.
- Clinical procedures: Chemical peeling (TCA 15–20%), laser toning — supportive aesthetic interventions.
Oily Skin, Enlarged Pores and Blackheads in PCOS
Androgen-driven sebum excess creates the conditions for enlarged pores, a shiny skin appearance, and comedonal acne formation. Concurrent barrier dysfunction perpetuates the inflammatory cycle.
At Virtuana Clinic, the oily skin-PCOS protocol operates on three levels:
- Home care: pH-balanced gel cleanser, 4–10% niacinamide (sebum-regulating + barrier-supporting), lightweight moisturiser, broad-spectrum SPF 50
- Clinical treatments: Salicylic acid peeling (20–30%), carbon laser peeling (carbon particle + Nd:YAG), hydroxyapatite-based mesotherapy (pore-tightening)
- Hormonal control: With androgen suppression, sebum production gradually normalises over months; pores become smaller
Integration of Hormonal Treatment with Aesthetic Approaches: The Integrated Model
In PCOS, local aesthetic interventions alone do not yield sustainable results; procedures performed without correcting the hormonal substrate provide only temporary benefit. The evidence-based integrated treatment model rests on four pillars:
| Pillar | Intervention | Goal |
|---|---|---|
| 1. Hormonal Balance | CHC, spironolactone, metformin | Normalise androgen and insulin levels |
| 2. Lifestyle | Low-GI diet, 150 min aerobic exercise per week, sleep hygiene | Improve insulin sensitivity, reduce inflammation |
| 3. Medical Aesthetics | Laser epilation, PRP, peeling, laser toning | Address existing skin and hair findings |
| 4. Daily Care | Personalised active-ingredient routine | Strengthen skin barrier, prevent recurrence |
Virtuana Clinic PCOS Protocol: Izmit/Kocaeli
At Virtuana Clinic in Kocaeli/Izmit, PCOS-related skin and hair problems are addressed through a multidisciplinary approach. During the initial consultation, a detailed hormonal panel analysis, trichoscopy, and skin photoanalysis assessment are performed, and an individualised treatment map is created.
PCOS aesthetic protocols applied at the clinic:
- Hormonal acne protocol (12 weeks): Salicylic acid/TCA peeling series + LED phototherapy (415 nm blue + 630 nm red) + retinoid home care
- Hirsutism protocol (6–12 months): 3 months of hormonal preparation → Nd:YAG 1064 nm laser epilation 6–8 sessions, at 4–6 week intervals
- Hair loss protocol (6 months): PRP (4 sessions, 4-week intervals) + LLLT device + stem cell mesotherapy cocktail; trichoscopy reassessment at 6 months
- Skin brightening protocol: Tranexamic acid + niacinamide mesotherapy + Q-switched Nd:YAG laser toning; 4–6 sessions
- Acanthosis nigricans protocol: TCA peeling + topical retinoid + metformin support (in collaboration with endocrinology)
Supportive Nutrition and Supplement Approaches in PCOS
Clinical evidence supports the benefit of certain nutrients on PCOS symptoms and skin manifestations:
- Myo-inositol + D-chiro-inositol (40:1 ratio): Improves insulin signalling; multiple RCTs have shown a 20–30% reduction in free testosterone levels. Improvement in skin findings has also been reported.
- Omega-3 fatty acids (EPA+DHA, 2–3 g/day): Reduces systemic inflammation, improves triglyceride profile, and attenuates acne severity.
- Vitamin D (1000–4000 IU/day, according to levels): Deficient in 67–85% of PCOS patients; has a modulatory effect on insulin sensitivity, androgen metabolism, and skin barrier function.
- Zinc (25–30 mg/day): 5-alpha reductase inhibitor; supportive for both inflammatory acne and hair loss. Zinc deficiency is common in PCOS.
- N-acetylcysteine (NAC, 600 mg twice daily): Glutathione precursor; reduces oxidative stress; positive data for insulin resistance and androgenic burden in PCOS.
- Berberine (500 mg 2–3 times daily): Metformin-like insulin-sensitising effect; may reduce skin inflammation via the gut-skin axis.
PCOS and Skin: Frequently Asked Questions
Can PCOS acne be cleared with topical products alone?
No. Aesthetic interventions performed without correcting the hormonal imbalance provide only temporary benefit. Systemic hormonal treatment and/or insulin-sensitising medications are essential for lasting results. Topical treatments serve a supportive role.
Is laser epilation effective in PCOS, or does it require continuous repetition?
As long as active hormonal stimulation continues, new follicular activation may occur. Laser epilation started after hormonal control is achieved produces significantly more effective results, and long-term success can be maintained with annual maintenance sessions.
Can PRP stop hair loss?
PRP enhances follicle vitality and positively influences the hair cycle. In PCOS, a marked synergistic effect is observed when combined with hormonal treatment. However, for a complete long-term solution, the underlying hormonal cause must be controlled.
How long does PCOS treatment take?
Initial improvement in skin findings is generally seen within 3–6 months. A meaningful response for hair loss may take 6–12 months. Permanent laser results for hirsutism consolidate within 12–18 months. As PCOS is a chronic condition, long-term follow-up and sometimes maintenance therapy may be required.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.